Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $729.9 million.

  • CG Oncology's Liabilities and Shareholders Equity rose 32.12% to $729.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 53.77%. This contributed to the annual value of $754.8 million for FY2024, which is 278.72% up from last year.
  • As of Q3 2025, CG Oncology's Liabilities and Shareholders Equity stood at $729.9 million, which was up 4.06% from $701.4 million recorded in Q2 2025.
  • CG Oncology's 5-year Liabilities and Shareholders Equity high stood at $754.8 million for Q4 2024, and its period low was $199.3 million during Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $640.3 million (2024), whereas its average is $601.2 million.
  • Data for CG Oncology's Liabilities and Shareholders Equity shows a peak YoY soared of 278.72% (in 2024) over the last 5 years.
  • CG Oncology's Liabilities and Shareholders Equity (Quarterly) stood at $199.3 million in 2023, then surged by 278.72% to $754.8 million in 2024, then surged by 32.12% to $729.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $729.9 million for Q3 2025, versus $701.4 million for Q2 2025 and $728.2 million for Q1 2025.